Company intelligence / Profile preview

Eyam Health

Vancouver, British Columbia, Canadaeyamhealth.com ↗

Ownership: Private
Development stage: Preclinical

Overview

The company has developed third-generation saRNA vaccines for SARS-CoV-2 that are undergoing preclinical trials in animals, with clinical trials anticipated to launch. They have tested 15 vaccines so far, including Omicron vaccines in preclinical models.

Therapeutic areas: OtherOncologyInfectious Diseases
Modalities: VaccinesImmunotherapeuticssaRNA vaccines
Industry: Biotech

Drug pipeline

2 assets

Gemini-enabled monoclonal antibodies for malaria

Preclinical

1 more asset in the full pipeline.

Request access →

Partnerships

Global Animal Health Leader

Beyond the preview

Go deeper on Eyam Health.

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on Eyam Health.

Explore the full profile